Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Hims & Hers stock could dive soon despite strong results
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Hims & Hers Health, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Hims & Hers Health, Inc. investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beat ...
Hims & Hers Health: Another Blowout Quarter Ignored
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
Hims & Hers price target raised to $21 from $18 at Piper Sandler
Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...
Becker's Hospital Review18h
Hims & Hers to sell generic weight loss drug in 2025
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
Seeking Alpha1d
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Hims & Hers price target raised to $32 from $28 at Seaport Research
Seaport Research raised the firm’s price target on Hims & Hers to $32 from $28 and keeps a Buy rating on the shares. The company ...
Hims & Hers Health Reports Better-Than-Expected Q3 Results: Details
Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the ...
Stocktwits on MSN1d
Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 Performance
Hims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...